Imago BioSciences, Inc. (IMGO): Price and Financial Metrics
IMGO Price/Volume Stats
|Current price||$36.01||52-week high||$36.09|
|Prev. close||$36.00||52-week low||$11.56|
|Day high||$36.02||Avg. volume||171,367|
|50-day MA||$29.83||Dividend yield||N/A|
|200-day MA||$19.59||Market Cap||1.22B|
IMGO Stock Price Chart Interactive Chart >
Imago BioSciences, Inc. (IMGO) Company Bio
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
IMGO Latest News Stream
|Loading, please wait...|
IMGO Latest Social Stream
View Full IMGO Social Stream
Latest IMGO News From Around the Web
Below are the latest news stories about IMAGO BIOSCIENCES INC that investors may wish to consider to help them evaluate IMGO as an investment opportunity.
The biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks.
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis
REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022
- 100% of patients treated with bomedemstat for ≥24 weeks (n=62 as of October 18, 2022) achieved a platelet count in the normal range with a median time to first normal platelet count of 10 weeks — - Of 28 patients treated with bomedemstat for 48 weeks, 89% (25/28) achieved a durable (≥12 weeks) platelet count in the normal range by week 48 - - 67% (20/30) of patients treated with bomedemstat experienced a decrease in mutant allele frequencies, including JAK2 and CALR – - All 5 patients with bas
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022
- As of the data cutoff of 18 October 2022, bomedemstat demonstrated spleen volume reduction in 66% (33/50) of patients and reduction in total symptom score in 65% (17/26) of patients at 24 weeks - - No patients in this Phase 2 study of bomedemstat in advanced myelofibrosis have progressed to acute myeloid leukemia while on treatment - - The Phase 2 study of bomedemstat in advanced myelofibrosis is fully enrolled, with an investigator-sponsored Phase 2 combination study of bomedemstat and ruxoli
RAHWAY, N.J., December 12, 2022--Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
IMGO Price Returns